SESSION LECTURE

No.35

Clinical Pharmacology and Clinical Research of New Drugs
Room: Swan Room 2

Co-Chairs:
Yimin Cui

Gerhard Rogler

Day 1 October 19th (Saturday) 14:00 – 17:10

Time	Speaker	Title
14:00-14:30	**Gerhard Rogler** University Hospital Zurich, Switzerland	Proton-sensing G-protein coupled receptors as new drug targets in fibrosis and cancer
14:30-15:00	**Jiong Shi** The First Affiliated Hospital of University of science and technology of China, China	Clinical trials of new drugs for AD
15:00-15:30	**Heyu Ni** University of Toronto, Canada	Platelets are versatile cells: potential new drugs against major human diseases
15:30-15:50	**Tea Break**	
15:50-16:10	**Xuemei Fan** Shanghai Jiao Tong University School of Medicine	An effective and safe strategy for anti-thrombosis therapy bymonoclonal antibody blocking the interaction of FIXa with FVIIIa
16:10-16:40	**Changhai Ding** Southern Medical University, China	Investigator initiated trials (IITs) in China
16:40-17:10	**Xiaofen Liu** Huashan Hospital affiliated to Fudan University, China	The Advancement of Antimicrobial Clinical Pharmacology in China

Yimin Cui

Cui.pharm@pkufh.com

Director of Institute of clinical pharmacology, Peking University. Pro.Cui is a leading expert in new drug evaluation and regulatory science in China. As a Principal Investigator (PI), he has been responsible for 171 clinical trials involving 112 investigational drugs. He has presided over a number of national, provincial and ministerial projects such as the national key R & D plan and the creation of major national new drugs; he has published more than 240 academic studies and more than 40 invention patents and software copyrights in nature reviews drug discovery, JAMA, STTT, JACC and other international authoritative magazines.

Jiong Shi

jshi2022@ustc.edu.cn

Vice president, The First Affiliated Hospital of University of Science and Technology of China. Dr. Shi is neurologist dedicated in neurological care and neuroscience research for more than 20 years. He has engaged in studying molecular mechanisms for neurodegenerative diseases,conducted preclinical studies and presided over more than 50 clinical trials, including the leading PI role for several pivotal clinical trials on Alzheimer's disease. He has authored more than 100 peer reviewed SCI papers in BMC, JAMA Neurology and etc. His current projects focus on the development of novel biomarkers and therapeutic agents for Alzheimer's disease.

Xuemei Fan

fanxuemei@sjtu.edu.cn

Dr. Xuemei Fan is a professor of Shanghai Jiao Tong University School of Medicine. Her main research interests are in basic research and translation underlying the platelets and coagulation factors related physiological and pathological processes, such as thrombopoiesis, thrombocytopenia, thrombosis and haemostasis and tumor metastasis. She has presided a number of projects such as NSFC program, national high-level young talent program, oriental talent program and Shanghai science and technology star program. Her findings have been published on Blood、JCI、Hepatology、Nature Comm、JTH、ATVB, etc., and applied for a number of patents.

Xiaofen Liu

xiaofenliu@fudan.edu.cn

Associate Professor, Institute of Antibiotics, Huashan Hospital affiliated to Fudan University, Shanghai, China She focuses on clinical pharmacology of antibiotics, including Phase I clinical trials for new antimicrobials, LC-MS/MS method development, therapeutic drug concentration monitoring (TDM), investigating pharmacokinetics (PK), population pharmacokinetic studies (PPK), antimicrobial pharmacokinetic/ pharmacodynamic (PK/PD). She is also interested in the study of antibiotic antibacterial mechanisms and resistance mechanisms, employing a systematic pharmacology approach.

Gerhard Rogler

Gerhard.Rogler@usz.ch

Professor Dr. Rogler's research is centered on inflammatory bowel disease (IBD), where he has played a pivotal role in advancing the Swiss IBD cohort study, significantly contributing to the understanding of the molecular mechanisms underlying genetic risk factors in the development of IBD. Another key area of his research involves the treatment of gastrointestinal diseases through modulation of the intestinal microbiota. His collaborative work in pioneering microbiome-based therapies has been instrumental in transforming treatment approaches for these conditions. Professor Rogler has authored over 680 publications and received numerous prestigious awards, including election to the German Academy of Sciences (Leopoldina) and the Academia Europaea.

Heyu Ni

Heyu.Ni@unityhealth.to

Fellow of Canadian Academy of Health Sciences, Professor of University of Toronto. Senior Scientist of the Canadian Blood Services. Platform Director for Hematology, Cancer and Immunological Diseases, St. Michael's Hospital. He is a leading immunologist and hematologist worldwide; is a reviewer of more than 40 internationally renowned journals, and is the reviewer for more than 20 research grant foundations in North America, Europe and Asia. He has made multiple breakthrough achievements in the diagnosis and treatment of immune diseases and thrombotic diseases, as well as the role and mechanism of platelets in bleeding disorders and thrombosis.

Changhai Ding

changhai.ding@utas.edu.au

Professor of Southern Medical University, executive director of clinical research center of Zhujiang Hospital, adjunct professor of University of Tasmania and Monash University in Australia; National distinguished experts, "Pearl River talent plan" introduced leading talents in scientific and technological innovation, and leading medical talents in Guangdong Province; The Secretary General of Guangdong clinical research quality control center, the chairman of the clinical research expert committee of Guangdong medical and health institutions, the director of the Council of the international Osteoarthritis Research Association, and the chairman of the OARSI research and Training Committee have been selected as the top 2% top scientists in the world for more than three consecutive years.